CRSP: Rega marang dodolan CRISPR Therapeutics Corp

Logo korporat perusahaan CRISPR Therapeutics Inc (CRSP)

CRISPR Therapeutics AG (CRSP) relies on a network of partner laboratories for the stable delivery of biomaterials. Experienced management under Samartit Chatterjee has successfully commercialized the first gene therapy. The current P/S multiple reflects these achievements, with the metric fixed at 155.70. This confirms the high value of cryogenic logistics, which guarantees the absolute preservation of drug properties.

CRSP: Multiplikator P/S CRISPR Therapeutics AG 04.07.2022 - 17.11.2026

Rincian analitis perusahaan CRISPR Therapeutics Inc (CRSP)

Ringkesan analitik perusahaan:CRSP CRISPR Therapeutics Corp
Barang unggulan CRISPR Therapeutics

Global clinical trials of CRISPR Therapeutics AG (CRSP) are subject to geopolitical risks and logistical disruptions, which directly impact the pace of technology commercialization. By analyzing the company's current P/S ratio, an investor assesses the market value of the business relative to its actual sales, determining the premium paid for future growth and evaluating the asset as a high-risk instrument with potential for revaluation upon changes in revenue.

Karo sapa CRISPR Therapeutics AG saingan

TEM (Tempus AI, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Qiagen Group - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IONS|RGEN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Avidity Biosciences RNA|Sema4 (WGS) - Rasio rega marang pendapatan|Rasio rega marang dodolan RARE (Ultragenyx)|Kapitalisasi marang pendapatan BEAM|Multiplikator P/S Sarepta Corp|Rasio rega marang pendapatan Twist Bioscience, Inc. (TWST)|Kapitalisasi marang pendapatan 10x Genomics TXG|Rasio rega marang pendapatan Intellia Therapeutics NTLA|Kapitalisasi marang volume dodolan STOK (Stoke Therapeutics, Inc.)|BLFS - Rasio rega marang pendapatan|Rega marang dodolan Wave Pharma|mazetx.com (MAZE) - Rasio rega marang pendapatan|SION - Koefisien rega marang pendapatan|PRME (Prime Medicine Inc) - Multiplikator P/S|Taysha Gene Therapies, Inc. - Rasio rega marang dodolan|Multiplikator P/S QURE|MGTX: Rasio rega marang dodolan|Rasio rega marang pendapatan REGENXBIO RGNX|SLDB: Rasio kapitalisasi marang pendapatan|OCGN: Kapitalisasi marang pendapatan|PACB - Multiplikator P/S|BNTC (Benitec Corp) - Kapitalisasi marang pendapatan|Multiplikator rega marang pendapatan Design Corp DSGN|Rasio rega marang pendapatan Rocket Pharmaceuticals|Multiplikator P/S 4D Molecular Therapeutics, Inc.|Rasio rega marang pendapatan Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EDIT (Editas Medicine, Inc.)|Multiplikator P/S Silence Therapeutics Corp SLN|PRQR - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Codexis Inc CDXS|SGMO: Multiplikator P/S|Rasio kapitalisasi marang pendapatan NAUT|Rasio rega marang pendapatan metagenomi.co|Multiplikator P/S Precision BioSciences Inc.|Multiplikator P/S GBIO|Boundless Bio, Inc. - Rasio kapitalisasi marang pendapatan|Multiplikator P/S XCUR (Exicure, Inc.)|Koefisien rega marang pendapatan Imunon, Inc. (IMNN)|PHIO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MBIO (mustangbio.com)|RNAZ: Multiplikator P/S|Rasio kapitalisasi marang pendapatan BNGO|APDN (Applied DNA Corp) - Multiplikator P/S|BLUE: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan ImmunoPrecise (IPA)|OMGA - Rega marang dodolan|Rasio rega marang pendapatan Singular Genomics OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology, Inc - Rasio kapitalisasi pasar marang pendapatan